Researchers presented interim results from the pilot PEER study of Aromasin, leuprolide, and Keytruda for HR-positive, HER2-negative advanced breast cancer.
The firm presented data at the AACR annual meeting that demonstrates its approach to treating HER2-positive solid cancers with engineered CAR macrophages.
A recent study suggests the lack of diversity in public databases may affect the accuracy of TMB scores and lead to inappropriate treatment for racial minorities.
The autologous, anti-BCMA CAR T-cell therapy may be the first to garner FDA approval for multiple myeloma patients but competing products may soon catch up.
Researchers are increasingly arguing that the tissue-agnostic approval was too broad, and that tumor mutational burden is only a biomarker of response to immunotherapy in a handful of cancer types.
The joint venture will use Veraxa Biotech's high-throughput technology to select antibodies against Indivumed's targets, beginning in colorectal and lung cancers.
The rate at which NGS-based algorithms generate obsolete trial matches is a system-wide information shortcoming, not a reflection of the tests themselves.
Medicare patients on FDA-approved cancer treatments in the real world do not live as long as patients in pivotal clinical trials, according to an MSK analysis.
